Drug Profile
Elranatamab - Pfizer
Alternative Names: Elranatamab-bcmm; ELREXFIO; ELREXFIOTM; PF-06863135; PF‑3135; RN-613Latest Information Update: 24 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Multiple myeloma
Most Recent Events
- 28 Feb 2024 PETHEMA Foundation plans a phase II trial for Multiple Myeloma (Second-line therapy or greater) in Spain (SC, Injection)(NCT06282978)
- 20 Feb 2024 Pfizer initiates the phase I trial for Multiple myeloma (Combination therapy, Second-line therapy or greater) in Canada (SC) (NCT06215118)
- 13 Feb 2024 Registered for Multiple myeloma (Second-line therapy or greater, Monotherapy) in Canada (SC)